The treatment of schizophrenia has evolved significantly over the years, with neuropsychopharmacological interventions remaining central to symptom management and improving patient outcomes. Schizophrenia, a complex and chronic psychiatric disorder, affects millions of individuals worldwide, posing significant challenges for healthcare systems, patients, and caregivers alike. The condition is characterized by symptoms such as delusions, hallucinations, disorganized thinking, and impaired cognitive functioning, necessitating a multifaceted therapeutic approach. This scoping review examines global trends in the prescription of neuropsychopharmacological agents for adults with schizophrenia, explores associated clinical correlates, and discusses the implications for clinical practice. Across the globe, antipsychotic medications serve as the cornerstone of schizophrenia treatment. These drugs are broadly categorized into two classes: typical (first-generation) and atypical (secondgeneration) antipsychotics.
HTML PDFShare this article
Pharmacoeconomics: Open Access received 106 citations as per Google Scholar report
